CTSO · Cytosorbents Corp · Executive Compensation
$5.43
+0.11 (+2.07%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“approximately $4.4 million in unrestricted cash and cash equivalents and $1.5 million of non-current restricted cash which may not be sufficient to fund the Company's operations beyond the next twelve months from the issuance of these condensed consolidated financial statements. These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$16.72M
Shares
3.14M
Volume · Oct 21
2138
Avg daily vol (30 sessions)
44.8K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD Chief Executive Officer | $808,431 |
| Vincent Capponi | MS President and Chief Operating Officer | $714,372 |
| Efthymios Deliargyris | Chief Medical Officer | $663,455 |
| Peter Mariani | CFO | $659,872 |
| Peter J. Mariani | Chief Financial Officer | $659,872 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, Chief Executive Officer | $899,695 |
| Vincent Capponi | MS President and Chief Operating Officer | $852,037 |
| Efthymios Deliargyris | Chief Medical Officer | $813,442 |
| Peter J. Mariani | Chief Financial Officer | $584,765 |
| Peter Mariani | CFO | $584,765 |
| Kathleen P. Bloch | Former Chief Financial Officer | $436,423 |
| Kathleen Bloch | CFO | $436,423 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, Chief Executive Officer | $1,333,402 |
| Vincent Capponi | MS President and Chief Operating Officer | $1,112,255 |
| Efthymios Deliargyris | Chief Medical Officer | $1,055,732 |
| Kathleen Bloch | CFO | $816,084 |
| Kathleen P. Bloch | Former Chief Financial Officer | $816,084 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD Chief Executive Officer | $1,790,596 |
| Vincent Capponi | MS President and Chief Operating Officer | $1,486,221 |
| Kathleen Bloch | CFO | $1,248,680 |
| Kathleen P. Bloch | MBA, CPA Chief Financial Officer | $1,248,680 |
| Efthymios Deliargyris | Chief Medical Officer | $1,194,718 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD Chief Executive Officer | $1,388,190 |
| Vincent Capponi | MS President and Chief Operating Officer | $1,178,697 |
| Kathleen Bloch | CFO | $970,871 |
| Kathleen P. Bloch | MBA, CPA Chief Financial Officer | $970,871 |
| Efthymios Deliargyris | Chief Medical Officer | $827,218 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD Chief Executive Officer | $1,404,376 |
| Vincent Capponi | MS President and Chief Operating Officer | $1,169,600 |
| Kathleen Bloch | CFO | $999,847 |
| Kathleen P. Bloch | MBA, CPA Chief Financial Officer | $999,847 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD Chief Executive Officer | $1,247,295 |
| Vincent Capponi | MS President and Chief Operating Officer | $1,079,620 |
| Kathleen P. Bloch | MBA, CPA Chief Financial Officer | $953,583 |
| Kathleen Bloch | CFO | $953,583 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Phillip Chan | MD, PhD President and Chief Executive Officer | $827,597 |
| Vincent Capponi | MS Chief Operating Officer | $713,438 |
| Kathleen Bloch | CFO | $626,614 |
| Kathleen P. Bloch | MBA, CPA Chief Financial Officer | $626,614 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kathleen P. Bloch | CFO | Retired | 2024-08-16 |
| Peter J. Mariani | Chief Financial Officer | Appointed | 2024-08-16 |
| Kathleen P. Bloch | Chief Financial Officer | Appointed | 2023-09-19 |
| Alexander D'Amico | Chief Financial Officer | Terminated | 2023-09-01 |
| Alexander D'Amico | Chief Financial Officer | Appointed | 2023-07-19 |
| Al W. Kraus | member of the Board | Retired | 2023-04-20 |
| Al W. Kraus | Chairman of the Board | Retired | 2023-04-20 |
| Kathleen P. Bloch | Interim Chief Financial Officer | Appointed | 2023-04-06 |
| Kathleen P. Bloch | Chief Financial Officer | Retired | 2023-04-06 |
| Kathleen P. Bloch | Chief Financial Officer | Retired | 2022-10-06 |
Leadership
- Phillip Chan CEO, Board Member
- Alexander D'Amico CFO
- Kathleen Bloch CFO
- Peter J. Mariani CFO
- Peter Mariani CFO
- Vincent Capponi COO
- Vincent J. Capponi, MS COO
- Alan D. Sobel Board Member
- Edward R. Jones Board Member
- Jiny Kim Board Member
- Michael G. Bator Board Member